As per the latest reports, the World Health Organization (WHO) stated on Saturday that it was ceasing its clinical trials of the antimalarial drug hydroxychloroquine (HCQ) and its combination with HIV drugs lopinavir/ritonavir. It was found that the mortality rate in hospitalized patients with COVID-19 was not mitigated.
The difficulty came as the WHO likewise announced in excess of 200,000 new cases universally of the ailment shockingly, in just one day. The United States reported 53,213 of the all out 212,326 new cases recorded on Friday, the WHO said.
WHO discontiues HCQ trial in hospitalised covid-19 patients but continues the evaluation of HCQ with lopinavir/ritonavir in non hospitalised patients. WHO is also considering at the potential use of Gilead’s antiviral drug remdesivir on COVID-19. The European Commission on Friday gave approval for remdesivir after noticing recuperation of the patients within stipulated time.
The multiple-country solidarity trial initiated by WHO, started with five trial arms to treat COVID-19: standard care; remdesivir; hydroxychloroquine (HCQ); lopinavir/ritonavir; and lopanivir/ritonavir blended with interferon as it looks for the survival improval.
US researchers are also hoping to combine other drugs like Baricitinib, and Tocilizumab, (which function as an anti-inflammatory) along with Remedesivir. They are commonly used for the prevention of rheumatoid arthritis.